On May 2, 2024, Transcarent, Inc. closed the transaction. The company announced that it has received $126,000,000 in a round of funding co-led by returning investors 7wire Ventures and General Catalyst Group Management, LLC. The transaction included participation from new investors Geodesic Capital, Memorial Hermann Healthcare System, Inc., and returning investors, Threshold Ventures Management Company, LLC, Kinnevik AB , Ally Bridge Group, Human Capital Investment Management LLC, Merck Global Health Innovation Fund, LLC, Alta Partners LP, Leaps by Bayer.

The transaction was raised at a post money valuation of $2,200,000,000. The company has raised a total of around $450,000,000 in funding till date.